Logo
Banner

Therapies Development Targeting Cell Wall Synthesis of A. Baumannii

One of the key factors contributing to the success of A. baumannii as a superbug is its cell wall, which provides protection against host defenses and antibiotics. As such, targeting cell wall synthesis represents an attractive approach for the development of new therapies against A. baumannii infections. At Ace Infectious, we offer a range of services aimed at developing therapies targeting the cell wall synthesis of A. baumannii.

Cell Wall Synthesis of A. Baumannii

The cell wall of A. baumannii consists of peptidoglycan, a mesh-like structure that provides structural integrity to the bacterium. The biosynthesis of peptidoglycan is a complex process that involves the coordinated activity of several enzymes, including transpeptidases and carboxypeptidases. The synthesis of the A. baumannii cell wall is essential for the survival and virulence of the bacterium. It's crucial to comprehend how A. baumannii synthesizes its cell wall as it could aid in creating novel antibiotics and treatments for addressing infections caused by this pathogen.

Targeting cell wall synthesis to combat bacterial resistance.Fig. 1 Targeting cell wall synthesis to combat bacterial resistance. (Sarkar P, et al., 2017)

Our Development Services

We offer a range of development services aimed at identifying and optimizing therapeutic candidates targeting the cell wall synthesis of A. baumannii. Our development services include target identification, hit discovery, lead optimization, and preclinical development. We work closely with our clients to understand their specific needs and tailor our services accordingly.

Target identification

Our team of experts can help you identify potential targets within the cell wall synthesis pathway of A. baumannii, using cutting-edge techniques such as high-throughput screening and bioinformatics analysis. We can then validate the targets using a range of in vitro and in vivo assays, including enzyme assays, cell-based assays, and animal models.

Hit discovery

Once we have identified potential hits, we can optimize them for potency, selectivity, and drug-like properties. Our team has extensive experience in medicinal chemistry, using a range of computational and synthetic chemistry techniques to design and synthesize novel compounds.

Lead optimization

After hit identification, we can select the most promising compounds for lead optimization, using a range of in vitro and in vivo assays to assess their safety, efficacy, and pharmacokinetic properties. Our team has expertise in developing small molecule and biologic-based therapies, including monoclonal antibodies and bacteriophages.

Preclinical development

Our preclinical development services include efficacy and safety studies, as well as toxicology and pharmacokinetic analysis. We can help you design and execute a comprehensive preclinical development plan that meets regulatory requirements and accelerates your path to clinical trials.

Several Different Approaches

  • Conduct high-throughput screening methods to discover small molecules.
  • Utilize structure-based drug design to produce potent inhibitors.
  • Discover antibacterial peptides that can disrupt the cell wall of A. baumannii.

Why Choose Us?

  • Our team of experts has with a proven track record of delivering innovative solutions to our clients.
  • We use cutting-edge technologies and state-of-the-art facilities to ensure that our clients receive the best possible service.
  • We provide regular updates and progress reports, and we are always available to answer questions and provide guidance throughout the development process.

If you are looking for a partner in the fight against A. baumannii and other superbugs, contact Ace Infectious today to learn more about our development services targeting cell wall synthesis. We look forward to working with you to develop innovative solutions that address this urgent global health threat.

Reference

  1. Sarkar P, et al. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Medchemcomm, 2017, 8(3): 516-533.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.